| Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients (NCT05073484) | Bio-Thera Solutions | 2021-10-29 |
| SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors (NCT05354843) | Etern BioPharma (Shanghai) Co., Ltd | 2021-10-27 |
| A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors (NCT05043298) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-10-27 |
| Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (NCT05101096) | Gilead Sciences | 2021-10-20 |
| A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors (NCT04914286) | Genfleet Therapeutics (Shanghai) Inc. | 2021-10-20 |
| A Study of HG381 Administered to Patients With Advanced Solid Tumors (NCT04998422) | HitGen Inc. | 2021-10-18 |
| Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors (NCT05101109) | ABL Bio, Inc. | 2021-10-06 |
| Study of LM-102 in Patients With Advance Solid Tumors (NCT05008445) | LaNova Medicines Development Co., Ltd. | 2021-10-06 |
| A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors (NCT05036291) | Ningbo Newbay Technology Development Co., Ltd | 2021-10-01 |
| A Study of HS269 in Patients With Advanced Solid Tumors (NCT05058352) | Zhejiang Hisun Pharmaceutical Co. Ltd. | 2021-10-01 |
| Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations (NCT05222165) | Helsinn Healthcare SA | 2021-10-01 |
| A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors (NCT05071183) | Turning Point Therapeutics, Inc. | 2021-09-23 |
| A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor (NCT05021367) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-09-23 |
| Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors (NCT04056910) | Jason J. Luke, MD | 2021-09-20 |
| To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors (NCT05014828) | BeiGene | 2021-09-18 |
| Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor (NCT05009966) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-09-16 |
| A Study of KL590586 in Patients With Advanced Solid Tumors (NCT05265091) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2021-09-15 |
| Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma (NCT04836195) | Pacylex Pharmaceuticals | 2021-09-14 |
| Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors (NCT04896697) | Xilio Development, Inc. | 2021-09-13 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (NCT05094804) | OncoResponse, Inc. | 2021-09-09 |
| Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation (NCT04890613) | Senhwa Biosciences, Inc. | 2021-09-08 |
| Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors (NCT05148325) | Bio-Thera Solutions | 2021-09-02 |
| A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers (NCT04973020) | Jiangsu HengRui Medicine Co., Ltd. | 2021-09-01 |
| The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor (NCT04871347) | Shandong TheraWisdom Biopharma Co., Ltd. | 2021-08-30 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma (NCT04851834) | Xennials Therapeutics Australia Pty Ltd | 2021-08-25 |
| RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors (NCT05052255) | Ryvu Therapeutics SA | 2021-08-13 |
| A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors (NCT06001580) | BioRay Pharmaceutical Co., Ltd. | 2021-08-11 |
| Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors (NCT04878484) | Athenex, Inc. | 2021-08-11 |
| GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors (NCT04977453) | GI Innovation, Inc. | 2021-08-02 |
| APL-102 Capsule in Patients With Advanced Solid Tumors (NCT05055518) | Apollomics Inc. | 2021-08-02 |
| Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors (NCT04906473) | Kunming Pharmaceuticals, Inc. | 2021-07-31 |
| A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC (NCT04849273) | Turning Point Therapeutics, Inc. | 2021-07-28 |
| Combining Epigenetic And Immune Therapy to Beat Cancer. (NCT04705818) | Institut Bergonié | 2021-07-23 |
| IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors. (NCT04912466) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-07-21 |
| A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors (NCT04801095) | Wellmarker Bio | 2021-07-14 |
| Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors (NCT04934514) | SUNHO（China）BioPharmaceutical CO., Ltd. | 2021-07-06 |
| The Absorption, Metabolism and Excretion of [14C]CM082 in Human (NCT04434326) | AnewPharma | 2021-07-05 |
| Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors (NCT04990739) | MetaboMed Inc | 2021-06-30 |
| A Phase I Study of BR790 in Subjects With Advanced Solid Tumors (NCT04891653) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2021-06-30 |
| A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors (NCT05291182) | Shouyao Holdings (Beijing) Co. LTD | 2021-06-28 |
| Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors (NCT04866641) | Taivex Therapeutics Corporation | 2021-06-24 |
| ALPN-202 With PD-1 Inhibition in Advanced Malignancies (NCT04920383) | Alpine Immune Sciences, Inc. | 2021-06-22 |
| Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors (NCT04892017) | Deciphera Pharmaceuticals, LLC | 2021-06-15 |
| A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer (NCT04872166) | Edgewood Oncology Inc. | 2021-06-07 |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers (NCT04802174) | National Cancer Institute (NCI) | 2021-06-01 |
| Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 (NCT04795713) | Molecular Templates, Inc. | 2021-05-27 |
| APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors (NCT04785196) | Ascentage Pharma Group Inc. | 2021-05-26 |
| A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer. (NCT04855929) | Anaveon AG | 2021-05-25 |
| Study of DNP002 in Patients With Solid Tumors (NCT06466265) | Kumho HT Inc. | 2021-05-24 |
| Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors (NCT04886271) | Hangzhou Hanx Biopharmaceuticals, Ltd. | 2021-05-12 |
| Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies (NCT04865159) | Kura Oncology, Inc. | 2021-05-06 |
| Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study (NCT04675528) | Daehwa Pharmaceutical Co., Ltd. | 2021-05-04 |
| Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors (NCT04855656) | Debiopharm International SA | 2021-04-30 |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer (NCT04659629) | Neurogene Inc. | 2021-04-26 |
| JAB-3068 Activity in Adult Patients With Advanced Solid Tumors (NCT04721223) | Jacobio Pharmaceuticals Co., Ltd. | 2021-04-26 |
| A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors (NCT04859777) | Monopteros Therapeutics Inc. | 2021-04-13 |
| Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II） (NCT04687423) | Fochon Pharmaceuticals, Ltd. | 2021-04-13 |
| Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours (NCT04855435) | MonTa Biosciences ApS | 2021-04-12 |
| Neoantigen-expanded Autologous Immune Cell Therapy (NCT05020119) | Chang Gung Memorial Hospital | 2021-04-09 |
| PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates (NCT04887194) | Mirati Therapeutics Inc. | 2021-04-08 |
| A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors (NCT04843033) | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 2021-04-02 |
| This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors (NCT04762641) | ABL Bio, Inc. | 2021-04-01 |
| A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors (NCT04761198) | Mereo BioPharma | 2021-03-23 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (NCT04772989) | Arcus Biosciences, Inc. | 2021-03-19 |
| Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors (NCT05382936) | Stemline Therapeutics, Inc. | 2021-03-19 |
| A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors (NCT04799054) | Ascendis Pharma Oncology Division A/S | 2021-03-18 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT04742959) | TransThera Sciences (Nanjing), Inc. | 2021-03-14 |
| Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment (NCT05101265) | PharmaMar | 2021-03-09 |
| A Study of KF-0210 in Advanced Solid Tumors Patients (NCT04713891) | Keythera Pharmaceuticals (Australia) Pty Ltd | 2021-03-09 |
| BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors (NCT04649385) | BeiGene | 2021-03-04 |
| First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors (NCT04761601) | 1200 Pharma, LLC | 2021-03-03 |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967) | NKGen Biotech, Inc. | 2021-03-01 |
| A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer (NCT04557384) | Eli Lilly and Company | 2021-02-23 |
| Meaning-Centered Pain Coping Skills Training (NCT04431830) | Duke University | 2021-02-09 |
| Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors (NCT05072106) | PharmaMar | 2021-01-14 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor (NCT04719065) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-01-13 |
| Dose Escalation Study of Immunomodulatory Nanoparticles (NCT04751786) | Radboud University Medical Center | 2021-01-11 |
| Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations (NCT04488003) | BioMed Valley Discoveries, Inc | 2021-01-07 |
| Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours (NCT04735978) | Replimune, Inc. | 2020-12-29 |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 (NCT04805307) | Keymed Biosciences Co.Ltd | 2020-12-24 |
| Study of M4344 in Combination With Niraparib (NCT04655183) | EMD Serono Research & Development Institute, Inc. | 2020-12-01 |
| Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients (NCT04638491) | Luye Pharma Group Ltd. | 2020-11-24 |
| Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma (NCT04609579) | Stingthera, Inc. | 2020-11-18 |
| A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects (NCT04457180) | Jiangsu HengRui Medicine Co., Ltd. | 2020-11-16 |
| A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT04682431) | Ikena Oncology | 2020-11-10 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors (NCT04622774) | ImmunoGen, Inc. | 2020-10-29 |
| A Study of PY314 in Subjects With Advanced Solid Tumors (NCT04691375) | Ikena Oncology | 2020-10-29 |
| A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors (NCT04472858) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-10-15 |
| A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors (NCT04440735) | Kahr Medical | 2020-10-07 |
| Tumor Molecular Profiling in Early Phase Clinical Trials (NCT04510766) | Oncology Institute of Southern Switzerland | 2020-10-01 |
| Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (NCT04592653) | Mural Oncology, Inc | 2020-09-30 |
| Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) (NCT04375228) | Columbia University | 2020-09-25 |
| Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors (NCT05155722) | Bio-Thera Solutions | 2020-09-17 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors (NCT04592484) | Codiak BioSciences | 2020-09-15 |
| Evaluate the Safety and Clinical Activity of HH2853 (NCT04390737) | Haihe Biopharma Co., Ltd. | 2020-09-08 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (NCT04242199) | Incyte Corporation | 2020-09-04 |
| Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors (NCT04478461) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2020-09-03 |